IMAGING OF MEDULLARY CARCINOMA OF THE THYROID USING IN-111 LABELED ANTI-CEA MONOCLONAL-ANTIBODY FRAGMENTS

被引:14
作者
OBYRNE, KJ
HAMILTON, D
ROBINSON, I
SWEENEY, E
FREYNE, PJ
CULLEN, MJ
机构
[1] Department of Endocrinology, St James's Hospital
[2] Department of Medical Physics and Bioengineering, St James's Hospital
[3] Department of Pathology, St James's Hospital
[4] Diagnostic Imaging Department, St James's Hospital
关键词
D O I
10.1097/00006231-199203000-00004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The distribution of In-111-labelled anti-carcinoembryonic antigen (CEA) monoclonal antibody fragments [F(Ab')2] was studied in five patients either with known inoperable medullary carcinoma of the thyroid (MCT) or evidence of recurrence/metastases based on elevated calcitonin (hCT) levels. All five cases had elevated serum CEA levels and positive immunohistochemical stains for both hCT and CEA prior to scintigraphy: In two patients with identified inoperable disease both planar and SPECT scans were positive. In the remaining three patients, where the recurrence/metastatic sites were unknown, SPECT images were positive in two. Of these, only one had positive planar images. These results indicate that In-111-labelled anti-CEA F(Ab')2 scintigraphy, especially in conjunction with SPECT, is useful for the diagnostic evaluation of patients with MCT. The limiting factor of this technique is the high level of non-specific uptake, particularly in the liver, but improvements in the specificity of newer anti-CEA antibodies and the ability to label these with Tc-99(m) is addressing this problem.
引用
收藏
页码:142 / 148
页数:7
相关论文
共 26 条
[1]  
Hazard J.B., Hawk W.A., Crile G., Medullary (Solid) carcinoma of the thyroid: A clinicopathological entity, J Clin Endo Metab, 19, pp. 152-161, (1959)
[2]  
Deftos L.J., Bone H., Parthemore J.G., Immunohisto- logical studies of medullary carcinoma of the thyroid and C cell hyperplasia, J Clin Endo Metab, 51, pp. 857-862, (1980)
[3]  
Melvin K., Miller H.H., Tashjian A.H., Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay, New Engl J Med, 285, pp. 1115-1119, (1971)
[4]  
Calmettes C., Monreteer M.S., Milland G., Correlation between calcitonin and CEA levels in medullary carcinoma of the thyroid, Biomed, 27, (1977)
[5]  
Busnardo B., Girelli M.E., Spreafico G., Bestagno M., Martino E., Moro A., Nacamulli D., Medullary thyroid carcinoma: A clinical co-operative study of 103 patients, XII Acta Endocrinologica Congress, (1981)
[6]  
Poston G.J., Thomas A., Macdonald D., Karvounaris D., Henderson B.L., George P., Lynn J.A., Lavender J.P., Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl quanidine, Nucl Med Coimmm, 7, pp. 215-221, (1986)
[7]  
Guerra U.P., Pizzocaro C., Terzi A., Giubbini R., Maira G., Pagliaini R., Bestagno M., New tracers for the imaging of the medullary thyroid carcinoma, Nucl Med Commun, 10, pp. 285-295, (1989)
[8]  
Udelsman R., Mojiminiyi O.A., Sopers N., Buley I.D., Shepstone B.J., Dudley N.E., Medullary carcinoma of the thyroid: Management of persistent hypercalcitonaemia utilizing [99, T, Tc](v) dimercaptosuccinic acid scintigraphy, Br J Surg, 76, pp. 1278-1281, (1989)
[9]  
Berche C., Mach J.-P., Lumbroso J.-D., Langlais C., Aubry F., Buchegger F., Carrel S., Roughier P., Parmentier C., Tubiana M., Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: First clinical results using radiolabelled monoclonal antibodies against carcinoem- bryonic antigen, Br Med J, 285, pp. 1447-1451, (1982)
[10]  
Parmentier C.J., Lumbroso J., Schlumberger M., Gardet P., Mach J.-P., Berche C., Rougier P., Caillou B., Tubiana M., Immunoscinitigraphie avec tomographie d'emission dans les cancers de la thyroide, Ann Med Interne, 135, pp. 345-350, (1984)